Latest News and Press Releases
Want to stay updated on the latest news?
-
NEW YORK, Jan. 06, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against agilon health, inc. (“Agilon” or the “Company”) (NYSE: AGL). Such investors are...
-
NEW YORK, Jan. 06, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against Fermi Inc. (“Fermi” or the “Company”) (NASDAQ: FRMI). Such investors are...
-
NEW YORK, Jan. 06, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against Charming Medical Ltd. (“Charming” or the “Company”) (NASDAQ: MCTA). Such...
-
NEW YORK, Jan. 06, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against Smartsheet Inc. (“Smartsheet” or the “Company”) (NYSE: SMAR). Such investors...
-
NEW YORK, Jan. 06, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Galectin Therapeutics Inc. (“Galectin” or the “Company”) (NASDAQ: GALT). Such investors...
-
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of VirTra, Inc. - VTSI
NEW YORK, Jan. 06, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of VirTra, Inc. (“VirTra” or the “Company”) (NASDAQ: VTSI). Such investors are advised to...
-
NEW YORK, Jan. 06, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Corcept Therapeutics Incorporated (“Corcept” or the “Company”) (NASDAQ: CORT). Such...
-
NEW YORK, Jan. 06, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of New Era Energy & Digital, Inc. (“New Era” or the “Company”) (NASDAQ: NUAI). Such...
-
NEW YORK, Jan. 06, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Nutanix, Inc. (“Nutanix” or the “Company”) (NASDAQ: NTNX). Such investors are advised to...
-
NEW YORK, Jan. 06, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Zenas BioPharma, Inc. (“Zenas” or the “Company”) (NASDAQ: ZBIO). Such investors are...